Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 27.
doi: 10.1002/jcph.6125. Online ahead of print.

In Vivo Activity of Intestinal P-Glycoprotein and Hepatic Organic Anion Transporters Polypeptide in Pregnancy and Postpartum

Álef Machado Gomes Pego  1 , Maria Paula Marques  1 , Fernanda de Lima Moreira  2 , Tiago Paz  1 , Maria Martha de Barros Tarozzo  1 , Rogério Pereira Mattos  3 , Patrícia Pereira Dos Santos Melli  3 , Geraldo Duarte  3 , Ricardo Carvalho Cavalli  3 , Vera Lucia Lanchote  1
Affiliations

In Vivo Activity of Intestinal P-Glycoprotein and Hepatic Organic Anion Transporters Polypeptide in Pregnancy and Postpartum

Álef Machado Gomes Pego et al. J Clin Pharmacol. .

Abstract

This study investigates the influence of pregnancy on the in vivo activity of the intestinal P-glycoprotein (P-gp) and hepatic organic anion transporters polypeptide (OATP/BCRP) using, respectively, fexofenadine and rosuvastatin as probe drugs. Eleven healthy participants were investigated during the third trimester of pregnancy (Phase 1, 28 to 38 weeks of gestation) and in the postpartum period (Phase 2, 8 to 12 weeks postpartum). In both phases, after administration of a single oral dose of fexofenadine (60 mg) and rosuvastatin (5 mg), serial blood samples were collected for up to 24 h. Rosuvastatin and fexofenadine in plasma were analyzed by LC-MS/MS using previously validated methods. The pharmacokinetic parameters of fexofenadine and rosuvastatin (Phoenix WinNonLin software) with normal distribution (Shapiro-Wilk test) are presented as geometric mean and 90% confidence interval. Phases 1 and 2 were compared using the t test (P < .05). Fexofexadine AUC0-24 values do not differ (P-value: .0715) between Phase 1 (641.9 ng h/mL [500.6-823.1]) and Phase 2 (823.8 ng h/mL [641.5-1057.6]) showing that pregnancy (third trimester) does not alter intestinal P-gp activity. However, rosuvastatin AUC0-24 values are higher (P-value: .00005) in Phase 1 (18.7 ng h/mL [13.3-26.4]) when compared to Phase 2 (9.5 ng h/mL [6.7-13.4]), suggesting inhibition of OATP1B1/OATP1B3 transporters. In conclusion, pregnancy assessed during the third trimester does not alter the intestinal P-gp activity but reduces the activity of hepatic OATP1B1/OATP1B3 transporters. Therefore, adjustments in dosage regimens may be necessary for drugs with low therapeutic index, substrates of the OATP1B1/OATP1B3 transporters, administered during the third trimester of pregnancy.

Keywords: OATP/BCRP; P‐gp; fexofenadine; pregnancy; probe; rosuvastatin.

PubMed Disclaimer

References

    1. Liao MZ, Gao C, Bhatt DK, Prasad B, Mao Q. Quantitative proteomics reveals changes in transporter protein abundance in liver, kidney, and brain of mice by pregnancy. Drug Metab Lett. 2018;12(2):145‐152.
    1. Chen X, Gao C, Han LW, et al. Efflux transporters in drug disposition during pregnancy. Drug Metab Dispos. 2024;52(9). doi:10.1124/dmd.123.001385
    1. Govindarajan R, Sparreboom A. Drug transporters: advances and opportunities. Clin Pharmacol Ther. 2016;100(5):398‐403.
    1. DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012;52:249‐273.
    1. Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P‐glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington Specialized Center of Research Study. Clin Pharmacol Ther. 2008;84 (2): 248‐253.

LinkOut - more resources